Article
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Pharmacogenetics and genomics - 1 Jan 2010
Harmsze Ankie, van Werkum Jochem W, Bouman Heleen J, Ruven Henk J, Breet Nicolien J, Ten Berg Jurrien M, Hackeng Christian M, Tjoeng Mathieu M, Klungel Olaf H, de Boer Anthonius, Deneer Vera H
Abstract excerpt
INTRODUCTION: The prodrug, clopidogrel, plays an important role in the prevention of thrombotic events in patients undergoing coronary stenting. However, a substantial number of atherothrombotic events still occur, which can partially be explained by heightened residual platelet reactivity. Several studies report that the genetic variation in CYP2C19 (*2) is associated with an impaired response to clopidogrel....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.